Skip to content
Review Open access

Chronic Kidney Disease Burden Across EU/EEA Countries: Structural Determinants, Mortality Convergence and Comparison of Global Burden of Disease Estimates with Vital Registration Data

Oct 2026 · Epidemiologia · Vol 7, pp. 152 · 0 citations · 30 references

TL;DR

The structural determinants examined did not explain cross-country differences in GBD-estimated CKD burden, and no consistent regional pattern emerged, and GBD-derived estimates alone are insufficient to infer diagnostic inequality between countries.

Abstract

Background and Objectives: Cross-country differences in chronic kidney disease (CKD) burden across Europe, as estimated by the Global Burden of Disease (GBD) study, are often interpreted as reflecting unequal diagnosis, yet this interpretation has rarely been examined against other data sources. This study examined associations between economic, social and environmental determinants and CKD prevalence and mortality across 29 European Union and European Economic Area countries, assessed convergence between 1990 and 2023, and compared GBD estimates with vital registration data. Materials and Methods: Age-standardized CKD prevalence, mortality and disability-adjusted life years were obtained from GBD 2023. Cross-sectional regression (2023; heteroskedasticity-consistent standard errors; n = 27), k-means cluster analysis, and sigma- and beta-convergence analyses were performed. GBD mortality was compared with Eurostat death rates for diseases of the kidney and ureter (ICD-10 N00–N29, 2011–2023). GBD input sources for CKD prevalence were reviewed for Estonia, Latvia, Lithuania and Austria. Results: No structural determinant was robustly associated with CKD prevalence or mortality, and outcomes did not differ significantly across the three-cluster typology (Kruskal–Wallis, p = 0.17–0.75). Mortality dispersion declined between the mid-1990s and the mid-2000s and stagnated thereafter. Prevalence dispersion increased marginally until the mid-2000s, with no significant trend from 2008 onward. Rank agreement between GBD and Eurostat mortality was moderate (ρ = 0.38 in 2023, down from 0.61 in 2017) and improved when diabetes deaths were added (ρ = 0.66). Estonia showed the largest discrepancy. Prevalence estimates for all four reviewed countries relied mainly on kidney replacement therapy registries, and no population-based source was identified for Latvia or Lithuania. Conclusions: The structural determinants examined did not explain cross-country differences in GBD-estimated CKD burden, and no consistent regional pattern emerged. Part of this variation is compatible with differences in cause-of-death coding and sparse local input data. GBD-derived estimates alone are therefore insufficient to infer diagnostic inequality between countries, and direct indicators of screening and detection are needed.

Read PDF

Similar papers

Oct 2026

Global, regional, and national burden and trends in chronic kidney disease attributable to metabolic risk, 1990-2021: based on global burden of disease data, 2021.

BACKGROUND Global chronic kidney disease (CKD) burden from metabolic risks has risen steadily. Using 2021 Global Burden of Disease (GBD) data, this study examines 1990-2021 spatiotemporal trends and regional disparities in CKD to inform prevention. METHODS We analyzed 1990-2021 GBD data on metabolic-related CKD burde...

Ke-Rong Jiang, Li-Min Yin, Yong-Sheng Pan et al. · 1 citation
Open access Sep 2026

Temporal Trends, Cross-Country Inequality, and Future Burden of Mortality and DALYs Attributable to High Fasting Plasma Glucose in South Asia, 1990–2050: Forecasting, Validation, and Benchmarking Analysis Using the Global Burden of Disease 2023 Study

Background & Objective: High fasting plasma glucose (HFPG) is a major modifiable metabolic risk factor for cardiovascular disease, chronic kidney disease, premature mortality, and disability. South Asia faces a growing cardiometabolic burden, yet long-term country-level trends, inequalities, and future HFPG-attributabl...

Muhammad Shoaib Khan, Suleman Khan, Safia Wazir et al. · 0 citations
Open access Sep 2026

Global, Regional, and National Burden of Heart Failure, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study 2023.

Importance Heart failure (HF) is a common condition with substantial geographical variation in its prevalence and underlying etiologies. Consistent and comparable data on the burden of HF within populations are needed to inform health system priorities. Objective To estimate the global burden of HF. Design, Setting...

Catherine O. Johnson, Madineh Abbasi, M. Abbasifard et al. · 2 citations
Open access Oct 2026

Trends, cross-country inequalities and risk factors in the global burden of chronic obstructive pulmonary disease mortality, 1990–2021: a secondary data analysis of the Global Burden of Disease Study 2021

Differentiated prevention and control strategies targeting low SDI regions, with attention to gender and older population differences, are needed to address key risk factors and reduce health inequalities.

Yu Sun, Shu Li, Dan Xu et al. · 0 citations
Open access Sep 2026

Global Trends in Cardiovascular Mortality and Major Cardiometabolic Risk Factors, 2000 to 2023: A Longitudinal Ecological Analysis of 204 Countries and Territories

Background and Aims: Cardiovascular disease (CVD) remains the leading cause of global mortality. We evaluated 24 year global trends in age-standardized CVD mortality across 204 countries and territories (2000-2023) and decomposed the independent longitudinal associations of major cardiometabolic risk factor pathways. M...

K. M. Al-Dhayani · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.